Novo Nordisk pipeline setback priced in
The discussion argued that Novo Nordisk's ~9% drop was roughly commensurate with the lost pipeline value ($5-10B opportunity) and that sentiment is so low the stock is de-risked.
Sign in to read the full idea
The argument, what validates it, the risks discussed and hearing it from the source are for signed-in members. Free accounts read 3 ideas in full a day. No card required.